Popular Articles
Stretch Mark

House Committee Approves Reform Bill; Full House Debate Scheduled For After August Recess
The House Energy and Commerce Committee on July 31 approved its health care reform bill (HR 3200) by a 31-28 vote that was mostly along party lines, the AP/Seattle Times reports. Among the many amendments considered during the markup, the committee rejected an amendment offered by Reps. Joe Pitts (R-Pa) and Bart Stupak (D-MI) to prohibit government subsidies to any insurance plans that offers abortion coverage, effectively prohibiting abortion coverage for customers eligible for public premium assistance. The amendment was rejected by a 27-31 vote. Another provision approved on July 30 would neither require nor prohibit insurance companies from providing coverage for abortion services.The approved bill includes provisions limiting how much insurers can increase premiums and gives the federal government the power to negotiate with drug companies for lower prices under Medicaid. The provisions were part of an effort by Democrats on the committee to reconcile the demands of liberals and conservatives, the AP/Times reports. The bill also would require insurance companies to sell coverage to anyone seeking it, regardless of pre-existing conditions. The government would provide subsidies to lower-income families to help them afford policies. In addition, the legislation would establish health insurance exchanges offering a variety of insurance plans, where consumers with or without subsidies could purchase health insurance (Espo/Werner, AP/Seattle Times, 8/1).Five of the committee"s Democrats joined all 23 Republicans in opposing the measure, the Washington Post"s "Capitol Briefing" reports. The five Democrats who voted against the bill were Reps. John Barrow (Ga.), Rick Boucher (Va.), Jim Matheson (Utah), Charlie Melancon (La.) and Bart Stupak (Mich.) (Kane, "Capitol Briefing," Washington Post, 7/31).The committee was the last of three House panels to take action on the legislation, although the vote comes several weeks after the White House and Democratic leaders originally wanted, the AP/Times reports. The full House is expected to vote on the bill after policymakers return from their August recess.Although the House"s agenda has moved slower than party leaders had hoped, it still was faster than the action in the Senate, according to the AP/Times (AP/Seattle Times, 8/1). Senate Finance Committee Chair Max Baucus (D-Mont.) on July 30 announced that the panel will not mark up a health care reform bill this week after Republican negotiators urged that the speed of discussion in the Senate be slowed, the Post"s "44" reports. The announcement means that health care reform legislation will not be out of committee in both chambers before the summer recess (Pershing, "44," Washington Post, 7/31).Catholic Bishops Say That House Bill Could Expand Abortion Coverage In related news, the U.S. Conference of Catholic Bishops in a letter to members of the House Energy and Commerce Committee voiced its opposition to the reform bill, arguing that it could be used to require private health insurance plans to cover abortion services, the Post reports. The bill has been opposed by conservative Christian groups for weeks, with the groups arguing that it could be used to expand abortion rights, the Post reports.In the letter, Cardinal Justin Rigali -- chair of the Committee on Pro-Life Activities -- said the bill could increase federal funding for abortion services because some government funding would not be covered by the Hyde Amendment, which currently bans the use of federal Medicaid funds for abortion services. Rigali also said the bill could overturn state laws that restrict access to abortion services, such as parental notification laws. In addition, Rigali said the bill should continue to ensure provider conscience rights to protect Catholic health care workers who refuse to provide abortion services based on their religious or moral beliefs (Washington Post, 8/1).
generic viagra online
What Is Gastroenteritis? What Is Food Poisoning?
Gastroenteritis means irritation and inflammation of the gastrointestinal tract, which includes the stomach and small and large intestines. The condition is usually due to bacteria, food poisoning, parasites, or viruses, and it often results in diarrhea, abdominal pain, nausea, and vomiting. Gastroenteritis is commonly called gastric flu or stomach flu although it has no relation to the influenza virus.
News of the day
Expert Researchers To Discuss Neutropenia, Recent Research
The National Neutropenia Network (NNN) and the Severe Chronic Neutropenia International Registry (SCNIR) will host the 9th Annual Neutropenia Family Conference in Ann Arbor, Mich., on July 24-26, at the Marriott Ypsilanti at Eagle Crest.
Medical Devices

New Data Supports Significant Economic And Clinical Value Of MENOPUR(R) In IVF

New data from an economic analysis presented today at this year"s European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).1 The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget. In today"s difficult global financial situation, the cost-effectiveness of infertility treatments, such as IVF, is more important than ever. Experiencing fertility problems is deeply distressing and isolating for couples and the cost of treatment is one of many considerations for people seeking treatment. A recent audit of European infertility patient groups showed that infertile couples are calling for clear information on the cost-effectiveness, as well as the efficacy of individual treatments.2 HP-hMG and rFSH are two commonly used hormonal therapies belonging to the class of drugs known as gonadotropins that enhance egg production in IVF treatment. HP-hMG, contains both FSH and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). In contrast, rFSH is a recombinant product and contains only rFSH. "Until recently, discussions regarding funding for infertility treatment services have been hindered by a relative paucity of economic studies of the specific treatments," points out study investigator Dr Jaro Wex from PharmArchitecture, UK. "Our new study compared success rates and value for money of gonadotropins in IVF and this work is likely to have a major impact on the decision-making process with respect to IVF treatment. The study showed that HP-hMG is a more attractive option than rFSH within a fixed budget, as it offers considerable cost savings over rFSH, not only in terms of costs per treatment cycle, but also in costs per live births." Health economic data The new study determined the cost-effectiveness of different gonadotropins in IVF cycles involving frozen embryo transfers using a simulation model. The economic evaluation compared HP-hMG and rFSH using individual patient data (n=986) pooled from two large, randomised, multi-national, non-inferiority trials (EISG3 and MERiT4)5. The simulation model used both live-birth data for the compared products and published UK costs of IVF related medical res. The main objectives were to determine for each patient starting treatment consisting of one fresh and up to two cryo or fresh cycles: (1) number of live-births (2) average cost of treatment; (3) average cost per live-birth; (4) incremental cost-effectiveness; (5) impact of inclusion of maternal and neonatal costs arising from successful pregnancies. After a sequence of one fresh and up to two frozen or fresh cycles, the cumulative live-birth rate was 53.7% for HP-hMG and 44.6% for rFSH (pMENOPUR MENOPUR belongs to a class of drugs known as gonadotropins and contains both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). HP-hMG is used to stimulate the development of multiple follicles in women participating in an ART programme. HP-hMG is also used to treat infertility in women caused by anovulation (low-level production of eggs). MENOPUR is used by over 75,000 patients each year and is currently licensed in over 50 countries across the world Ferring Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):